MNG518
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.519
- ALLOGRAFT_REJECTION+0.506
- INFLAMMATORY_RESPONSE+0.464
- IL6_JAK_STAT3_SIGNALING+0.440
- KRAS_SIGNALING_UP+0.357
- INTERFERON_GAMMA_RESPONSE+0.327
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.286
- COAGULATION+0.275
- KRAS_SIGNALING_DN+0.254
- IL2_STAT5_SIGNALING+0.248
Top 10 suppressed
- MYC_TARGETS_V1-0.565
- PROTEIN_SECRETION-0.557
- OXIDATIVE_PHOSPHORYLATION-0.505
- MYC_TARGETS_V2-0.488
- UNFOLDED_PROTEIN_RESPONSE-0.480
- DNA_REPAIR-0.457
- E2F_TARGETS-0.434
- NOTCH_SIGNALING-0.380
- MTORC1_SIGNALING-0.373
- PEROXISOME-0.363
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1358561 | GTEX | — | 0.943 |
| 2 | SRR26320079 | — | — | 0.940 |
| 3 | SRR607445 | GTEX | — | 0.930 |
| 4 | SRR1103048 | GTEX | — | 0.928 |
| 5 | SRR1335446 | GTEX | — | 0.927 |
| 6 | SRR6013478 | — | cohortMD2 | 0.923 |
| 7 | SRR601201 | GTEX | — | 0.922 |
| 8 | SRR1394343 | GTEX | — | 0.922 |
| 9 | SRR603658 | GTEX | — | 0.918 |
| 10 | SRR1414424 | GTEX | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.519 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.506 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.464 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.357 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.327 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.286 | Inavolisib | — uncovered |
| COAGULATION | 0.275 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.254 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.248 | Idelalisib | — uncovered |
| COMPLEMENT | 0.237 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.235 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.214 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.186 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.066 | Inavolisib | — uncovered |
| APOPTOSIS | 0.062 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.022 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.021 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.015 | Temsirolimus | — uncovered |